AW
NRIX icon

Avion Wealth’s Nurix Therapeutics NRIX Stock Holding History

Avion Wealth’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Hold
250
– – ﹤0.01% 803
2025
Q4 		$4K Hold
250
– – ﹤0.01% 717
2025
Q3 		$2K Buy
+250
New +$2.6K ﹤0.01% 884

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Avion Wealth's NRIX Position: Q1 2026 in Review

Avion Wealth held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 250 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

Avion Wealth first reported a position in NRIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $4K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Avion Wealth held 250 shares of Nurix Therapeutics worth $3K as of Q1 2026.
  • Avion Wealth left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Avion Wealth's portfolio in Q1 2026, its #803 holding.
  • Avion Wealth first reported a position in Nurix Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Avion Wealth's Nurix Therapeutics position peaked at $4K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Avion Wealth's 13F filing for Q1 2026, filed 1 May 2026.